Navigation Links
Echo Therapeutics Announces Management Changes
Date:8/26/2013

PHILADELPHIA, Aug. 26, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its non-invasive Symphony® CGM System as a needle-free, wireless continuous glucose monitoring system, today announced that its Chief Executive Officer, President and Chairman of the Board, Dr. Patrick Mooney, is taking an immediate leave of absence.  Robert Doman, a member of Echo's Board of Directors, will serve as Executive Chairman and Interim Chief Executive Officer. 

Mr. Doman has over 30 years of executive level, international and domestic management, business development, sales and marketing, product development and strategic planning experience with specific concentrations in medical devices and pharmaceuticals.  Most recently, Mr. Doman served as President and Chief Executive Officer of publicly-traded DUSA Pharmaceuticals, Inc., which was successfully sold to Sun Pharmaceuticals in a $230 million transaction in 2012. 

Effective immediately, William Grieco, Chairman of the Company's Nominating and Corporate Governance Committee and a member of Echo's Board since February 2011, has been appointed Lead Independent Director of the Board. 

"Echo's business operations will continue as usual in Dr. Mooney's absence," said Mr. Doman.  "We remain focused on completing our ongoing clinical studies and filing the Symphony CGM System technical file for CE Marking in the near future."

The Board of Directors will be engaging an executive search firm to assist it in identifying a new CEO.  Mr. Grieco commented, "We're extremely fortunate to have Bob serving as Executive Chairman and Interim CEO at this critically important juncture for the Company." 

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for use initially in the critical care setting.   Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, statements regarding the CEO's leave of absence and company performance. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information: 

Seth Lewis
Senior Vice President
The Trout Group, LLC
+1 646 378 2952

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
2. aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
3. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
4. PTC Therapeutics Reports Second Quarter 2013 Financial and Corporate Results
5. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
6. Breckenridge Enters Into Agreement to Acquire Certain Cypress Assets from Pernix Therapeutics
7. Northwest Biotherapeutics Announces Registered Direct Offering
8. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
9. Echo Therapeutics Announces Second Quarter 2013 Financial Results
10. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
11. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Many patients don,t realize that ... when a pharmacy just a few blocks away charges ... this problem Medicationdiscountcard.com has created a price ... how much their medication will cost at most nearby ... Medicationdiscountcard.com takes all of ...
(Date:1/19/2017)... CITY, Calif. , Jan. 19, 2017  Abaxis, ... company manufacturing point-of-care blood analysis instruments and consumables for ... conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on ... results for the third quarter fiscal year 2017 after ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange ... excited to announce that the first five replication ...  (RP:CB) have been published in eLife today. Despite ... represents the first practical evaluation of reproducibility rates ... reproducible studies. Unlike other assessments of reproducibility, the ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Aerolib Healthcare Solutions ... Clinical and Regulatory education for Physicians, Physician Advisors, Case managers, Utilization Review ... of Disease Specific Documentation Improvement. , The Aerolib Learning Management System is ...
(Date:1/19/2017)... ... 19, 2017 , ... LabRoots , the leading provider ... world, announces the launch of its newly redesigned website. The sleek new design ... and trending news, vital information on upcoming virtual events and webinars, all while ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... Gattefossé, the leader in innovative excipients and drug delivery solutions to health industries ...
(Date:1/19/2017)... ... ... Students interested in video can get a jump start on their education ... $1,000 scholarship and have his or her video posted on the GenCure website and ... with the winner announced on June 9. , The competition is designed to help ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Sam & Associates ... to commercial and residential clients in the California Bay Area, is launching a charity ... in the region. , Heart disease is the primary killer of adult men and ...
Breaking Medicine News(10 mins):